Scientists have long tried to duplicate the procedure that led to the first long-term remission 12 years ago. With the so-called London patient, they seem to have succeeded.

New Phase 3 AMBER study data continues to demonstrate high rates of virologic suppression at 96 weeks in ART-naïve adults with HIV-1 when treated with D/C/F/TAF.

The number of HIV patients that underwent treatment in Q1 2018 did not change in Latvia even though a considerable amount of funding was allocated from the state budget for HIV/AIDS treatment in 2018. This creates concerns about HIV patients’ use of healthcare services, according ...

Therapies to prevent infection are advancing in a crowded field.

New study provides insights into the factors that influence HIV treatment adherence in Latin America and the Caribbean. Results show that individuals from lower resource settings often achieve higher levels of adherence, contrary to predictions.

One injection of the cloned antibody significantly reduced participants’ viral load in a recent advanced trial.

Since now only the latest non-interferon therapy for the treatment of chronic HCV will be prescribed to all patients in Latvia.

The guide explains what global standards are for TB prevention, treatment, and care, so people with TB and their caregivers can know what services they have the right to receive.

The efficacy of antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug–polymer matrices which achieved week-long systemic drug levels ...

The beginning of 2018 brings forth positive changes in the treatment of HIV-positive patients: additional budget funding will allow to increase the CD4 immune cells level at which the patients are eligible to start a governmentally-funded therapy, which is now 500 cells/mcl. Until this time, ...

Starting antiretroviral therapy (ART) immediately rather waiting until a person's CD4 count falls below 500 cells/µL has almost no impact on the person's risk of developing antiretroviral resistance over the next seven years, according to a study published online in the journal AIDS. In this ...

VITROS HIV Combo, a fourth-generation test, detects both HIV-1 and HIV-2 antibodies (Ab) and the p24 antigen (Ag), enabling HIV-1 acute infection detection earlier than third-generation tests.  

The drug was approved in India in November this year and is the “first” to be approved in eight years for the management of this infection here, Mylan added.

Brussels, 29 November 2017: Experts unveiled a set of recommendations on Wednesday to address health problems facing people living with HIV. Treatments are helping people with HIV live long lives, but they face higher risk than others of serious illnesses – from cancer to heart ...

An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to a sustained response in all people with HIV and genotype 1 or 4 hepatitis C virus (HCV) in the SWIFT-C study, according to a report at the AASLD Liver Meeting last month in Washington, DC.

A second-line HIV regimen containing the integrase inhibitor raltegravir failed to meet its primary endpoint of noninferiority against standard second-line treatment with nucleoside reverse-transcriptase inhibitors, or NRTIs, according to 144-week data from the EARNEST trial.

The system of efficient and transparent public procurement is the Republic is not yet established.

More than 100 experts in the HIV/AIDS response area from all over the country convened at a round table in Bishkek (Kyrgyz Republic) on November 13 to discuss the issues of increasing access to medicines and ensuring the transparent functioning of medical institutions. The meeting ...